Cancer Pain
Conditions
Interventions
This is a randomized, controlled, blinded, crossover study with patients with hematologic cancer undergoing treatment at the Oncology and Hematology Unit of the Hospital de Clínicas Complex of the Fed
E02.331.800
E02.190.599.750.750
E02.779
Sponsors
Universidade Federal do Paraná
Universidade Federal do Paraná
Eligibility
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Patients of both sexes diagnosed with hematologic cancer (leukemia, lymphoma, or multiple myeloma) undergoing active treatment (chemotherapy, immunotherapy, or radiotherapy); aged between 18 and 60 years; patients experiencing pain resulting from the tumor itself, from cancer treatment, or associated with the tumor (e.g., being bedridden or performing daily activities), regardless of location, with intensity greater than or equal to 4 on the Visual Analogue Scale, within the previous 24 hours; patients with the ability to verbally communicate in Portuguese; patients capable of providing informed consent; patients scoring between 0 and 3 on the ECOG-PS (Eastern Cooperative Oncology Group Performance Status).
Exclusion criteria
Exclusion criteria: Illiterate individuals; patients with psychiatric or cognitive disorders as determined by the opinion and/or follow-up of the attending psychologist; patients with hearing impairments that prevent comprehension of verbal instructions; pregnant or breastfeeding women; patients experiencing pain not directly or indirectly related to the tumor (i.e., chronic low back pain or pain resulting from musculoskeletal diagnoses such as arthritis or arthrosis); patients receiving other analgesic therapies such as radiation, bone cement, or nerve block therapy; individuals with known contraindications to massage therapy, including spinal tumors, known hematologic coagulation disorders (such as hemophilia, Von Willebrand disease, or thrombocytopenia), paresthesia, injuries (open wounds), post-surgical regions, catheters, and deep vein thrombosis (DVT); individuals with known contraindications to electrical stimulation, such as metallic electronic implants like pacemakers or metal at the electrode site, implanted neuromodulation devices, individuals with epilepsy or arrhythmia, dermatological conditions or fragile skin at the application site, and history of allergy to electrodes; use of analgesic or opioid medication during the intervention and data collection period (2 hours), outside of the patient’s regular prescription.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain reduction of 20% on the Visual Analogue Scale and 30% on the Brief Pain Inventory (BPI) scale, immediately after application, with a 1-hour follow-up | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of 3 points or more in Fatigue Cancer-related fatigue, through the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F), immediately after application, with a 1-hour follow-up;Change of 2 points or more in episodes of nausea, vomiting, muscle tension, stress and anxiety, through the 11-point numerical scale, immediately after application, with a 1-hour follow-up;20% reduction in analgesic and opioid consumption, recorded through patient diary and protocols, immediately after application, with a 1-hour follow-up;2-point reduction in the Satisfaction Scale, measured through the Patient Global Impression of Change (PGI-C), immediately after application, with a 1-hour follow-up 1 hour | — |
Countries
Brazil
Contacts
Public ContactRaciele Korelo
Universidade Federal do Paraná
Outcome results
None listed